Skip to main content
. 2006 Sep 1;56(5):627–640. doi: 10.1007/s00262-006-0220-0

Fig. 4.

Fig. 4

Combined treatment of A498 kidney cancer cells with bv-sPLA2 and PtdIns(3,4)P2 reduces cell surface expression of the EGFR. Cells were left untreated (C control), were treated with bv-sPLA2 (100 μg/ml), with PtdIns(3,4)P2 (100 μM) or a combination thereof as indicated. Expression of the EGFR was determined by flow cytometry. Shown is a representative of three independently performed experiments